hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate
CORTISPORIN (hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate) by Monarch Therapeutics is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1963.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
Cortisporin is a topical triple-antibiotic and corticosteroid cream combining hydrocortisone acetate, neomycin sulfate, and polymyxin B sulfate. It treats superficial bacterial infections of the external auditory canal caused by susceptible organisms including Staphylococcus aureus and gram-negative bacteria. The combination works by disrupting bacterial cell membranes (polymyxin), inhibiting protein synthesis (neomycin), and reducing inflammation and edema (hydrocortisone).
This mature, legacy product approaching loss of exclusivity signals potential team consolidation and reduced commercial investment at Monarch Therapeutics.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on CORTISPORIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Cortisporin offers limited career growth opportunity given its legacy status and approaching LOE, but provides exposure to defensive commercial strategy, generic competition management, and portfolio optimization at Monarch Therapeutics. Roles on this product are shrinking rather than expanding, making it suitable only for professionals seeking stability in a mature portfolio rather than career advancement.